Oral therapy for Peyronie's disease.
Peyronie's disease (PD) remains a therapeutic dilemma for the urologist. Despite a myriad of medical therapies proposed for PD there have been limited advances in oral medical treatment. Several new approaches are presented which hold promise of success, although a definitive medical therapy for PD has yet to be established. Since early stage disease is reputed to respond better than well-established plaques, an early trial of inexpensive, safe and well-tolerated oral therapy is often initially recommended. This review discusses the historical aspects as well as contemporary oral medical therapy for PD. With advances in the molecular biology of inflammation and wound healing, the management and understanding of this frustrating disease will no doubt improve.
Mynderse
L A
LA
Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA. mynderse.lance@mayo.edu
Monga
M
M
D010129:4-Aminobenzoic Acid / Q000008:administration & dosage*; D000284:Administration, Oral; D000975:Antioxidants / Q000008:administration & dosage*; D003078:Colchicine / Q000008:administration & dosage*; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010411:Penile Induration / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage*; D014810:Vitamin E / Q000008:administration & dosage*
D000975:Antioxidants; D004965:Estrogen Antagonists; D013629:Tamoxifen; D014810:Vitamin E; D003078:Colchicine; D010129:4-Aminobenzoic Acid